Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2025-01-17 00:00:00 ET · period of report 2025-01-17 · accession 0001628280-25-001900 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-17 | 2025-01-17 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $273.41 | -442 | 5,058 | -8% | -$120.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-17 | S | D | 442 | $273.41 | 5,058 | D | — | — |